Lilly Expands Beyond Weight-Loss Drugs with New Acquisitions
Lilly Seeks New Growth Beyond Weight-Loss Drugs
Eli Lilly is expanding beyond its blockbuster GLP-1 weight-loss medications through strategic acquisitions. The company reported promising results for Verve-102, an experimental cell therapy that significantly lowers LDL cholesterol. It also acquired three vaccine developers to enter the infectious disease space.
Verve-102 Shows Promise in Cholesterol Reduction
A single infusion of Verve-102 reduced PCSK9 protein levels by up to 88% and lowered LDL cholesterol by 62%. The therapy targets patients with premature coronary artery disease and genetic cholesterol disorders. Phase 1b studies are ongoing, and the FDA has granted fast-track status.
Expanding into Infectious Diseases
Lilly acquired Curevo, LimmaTech Biologics, and Vaccine Co. to develop vaccines against shingles, bacterial infections, and Epstein-Barr virus. This move aligns with Lilly's strategy to explore women's health and infectious diseases beyond its core areas.
Lilly's financial strength, fueled by its weight-loss drug Foundayo, supports these acquisitions. The company maintains a dominant position in the GLP-1 market while pursuing new growth avenues.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…